Patents by Inventor Robert A. Lahti

Robert A. Lahti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
    Patent number: 6133446
    Abstract: Novel aromatic bicyclic amines of formula (I) ##STR1## are useful in treating central nervous system disorders and cardiac arrhythmias and cardiac fibrillation.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: October 17, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Ruth E. TenBrink, Michael D. Ennis, Chiu-Hong Lin, Robert A. Lahti, Arthur G. Romero, John C. Sih
  • Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
    Patent number: 5877317
    Abstract: Novel aromatic bicyclic amines of formula (I) ##STR1## are useful in treating central nervous system disorders and cardiac arrhythmias and cardiac fibrillation.
    Type: Grant
    Filed: June 24, 1996
    Date of Patent: March 2, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Ruth E. TenBrink, Michael D. Ennis, Robert A. Lahti
  • N-(2-amino-cycloalkenyl)benzeneacetamide and -benzamide analgesics and tritiated kappa agonists therefrom
    Patent number: 4560767
    Abstract: Amino-cycloalkenyl-amide compounds, e.g., (1.alpha.,6.beta.)-(.+-.)-3,4-dichloro-N-methyl-N-(6-(1-pyrrolidinyl)-3-cy clohexen-1-yl)benzeneacetamide, and tritiated derivatives thereof, are useful as analgesics and as radio labeled compounds for pharmacological and metabolism studies in animals.
    Type: Grant
    Filed: June 17, 1983
    Date of Patent: December 24, 1985
    Assignee: The Upjohn Company
    Inventors: John M. McCall, Robert A. Lahti
  • Use of certain 1-substituted-triazolo-benzodiazepines to treat psychoses
    Patent number: 4472397
    Abstract: Certain 1-(Nitrogen-containing group)-triazolo-benzodiazepines, e.g., adinazolam, are useful for treating psychotic, including schizophrenic, conditions in human patients.
    Type: Grant
    Filed: February 18, 1983
    Date of Patent: September 18, 1984
    Assignee: The Upjohn Company
    Inventors: Robert Lahti, Robert E. Pyke
  • Method of treating depression
    Patent number: 4386079
    Abstract: A method of treating depression in humans which comprises administering orally to humans an antidepressant effective amount of a compound having the formula I.sub.1 wherein Y is alkyl of from 1 to 3 carbons, inclusive; A is ethylene or --CH.sub.2 CH(CH.sub.2 Cl)--, T and T.sub.1 are the same or different and are SR.sub.3, OR or NR.sub.1 R.sub.2 ; R is hydrogen, alkyl of from 1 through 6 carbons, aryl, aralkyl or I(a) with the proviso that when one of T or T.sub.1 is NR.sub.1 R.sub.2 then the other cannot be SR.sub.3 or OR.
    Type: Grant
    Filed: November 23, 1981
    Date of Patent: May 31, 1983
    Assignee: The Upjohn Company
    Inventor: Robert A. Lahti